Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Antibody / Recombinant Antibody

Anti-ACP3 Antibody (R1P65)

Catalog #:   RHD10102 Specific References (50) DATASHEET
Host species: Rabbit
Isotype: IgG
Applications: IF, IHC, IP, WB
Accession: P15309
Overview

Catalog No.

RHD10102

Species reactivity

Human, Mouse

Host species

Rabbit

Isotype

IgG

Clonality

Monoclonal

Tested applications

IF: 1:50-1:200, IHC: 1:100-1:200, IP: 1:20-1:50, WB: 1:1000-1:2000

Target

Prostatic acid phosphatase, Thiamine monophosphatase, ACPP, TMPase, ACP3, Protein tyrosine phosphatase ACP3, 5'-nucleotidase, Acid phosphatase 3, PAP, 5'-NT, Ecto-5'-nucleotidase

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P15309

Applications

IF, IHC, IP, WB

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.05% BSA, 50% Glycerol, 0.05% Sodium azide.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 4 ℃ for frequent use. Store at -20 ℃ for twelve months from the date of receipt.

Clone ID

R1P65

Data Image
  • Western blot
    Western blot analysis of Prostatic Acid Phosphatase expression in human prostate cancer lysate.
References

Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach., PMID:40449956

Plant-derived recombinant macromolecular PAP-IgG Fc as a novel prostate cancer vaccine candidate eliciting robust immune responses., PMID:40140219

Race-Related Differences in Sipuleucel-T Response among Men with Metastatic Castrate-Resistant Prostate Cancer., PMID:38856749

Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer., PMID:38101860

Co-transient expression of PSA-Fc and PAP-Fc fusion protein in plant as prostate cancer vaccine candidates and immune responses in mice., PMID:37269373

Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials., PMID:37058234

Avelumab in Men With Metastatic Castration-Resistant Prostate Cancer, Enriched for Patients Treated Previously With a Therapeutic Cancer Vaccine., PMID:36821354

Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)., PMID:35277461

Biochemical, molecular and cytological impacts of alpha-lipoic acid and Ginkgo biloba in ameliorating testicular dysfunctions induced by silver nanoparticles in rats., PMID:35067888

Targeting the spectrum of immune checkpoints in prostate cancer., PMID:34263692

TGM4: an immunogenic prostate-restricted antigen., PMID:34193566

Prostate Cancer Immunotherapy-Finally in From the Cold?, PMID:34125308

Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer., PMID:33986125

Antibody profiling of patients with prostate cancer reveals differences in antibody signatures among disease stages., PMID:33335027

Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-T., PMID:32967912

Putting the Pieces Together: Completing the Mechanism of Action Jigsaw for Sipuleucel-T., PMID:32145020

Bovine papillomavirus prostate cancer antigen virus-like particle vaccines are efficacious in advanced cancers in the TRAMP mouse spontaneous prostate cancer model., PMID:32016503

Immunohistochemical Reactivity of Prostate-Specific Markers for Salivary Duct Carcinoma., PMID:31865345

Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine., PMID:29534736

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment., PMID:28376158

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer., PMID:28361045

Purification of a Human Prostate Specific Antigen., PMID:28012750

[Preparation and activity validation of PP7 bacteriophage-like particles displaying PAP114-128 peptide]., PMID:27667462

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses., PMID:27471641

A Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers., PMID:26421725

Epithelial and stromal alterations in prostate after cypermethrin administration in adult albino rats (histological and biochemical study)., PMID:25987297

Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome., PMID:25649018

Glycoprotein fucosylation is increased in seminal plasma of subfertile men., PMID:25248658

Increased expression of GCNT1 is associated with altered O-glycosylation of PSA, PAP, and MUC1 in human prostate cancers., PMID:24854630

Label-free capacitive diagnostics: exploiting local redox probe state occupancy., PMID:24491045

Beyond sipuleucel-T: immune approaches to treating prostate cancer., PMID:24402184

Antinociceptive effect of prostatic acid phosphatase in a rat model of cancer-induced bone pain., PMID:24284839

Immunodominant semen proteins II: contribution of seminal proteins to female immune infertility., PMID:24280142

The immunohistochemical expression of islet 1 and PAX8 by rectal neuroendocrine tumors should be taken into account in the differential diagnosis of metastatic neuroendocrine tumors of unknown primary origin., PMID:24037217

Simultaneous and combined detection of multiple tumor biomarkers for prostate cancer in human serum by suspension array technology., PMID:23567627

Integration of immunotherapy into the management of advanced prostate cancer., PMID:23040162

The evolving role of immunotherapy in prostate cancer., PMID:22918924

Mass spectrometry-based proteomics as a tool to identify biological matrices in forensic science., PMID:22843116

An artificial PAP gene breaks self-tolerance and promotes tumor regression in the TRAMP model for prostate carcinoma., PMID:22086231

Barcode lateral flow immunochromatographic strip for prostate acid phosphatase determination., PMID:21880451

Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy., PMID:21670078

[Alternative tests to PSA for prostate cancer diagnosis]., PMID:21553390

Sipuleucel-T: Prototype for development of anti-tumor vaccines., PMID:21243538

Human cytokine response to Texas crotaline envenomation before and after antivenom administration., PMID:20887908

NKX3.1 as a marker of prostatic origin in metastatic tumors., PMID:20588175

Diagnostic utility of P504S/p63 cocktail, prostate-specific antigen, and prostatic acid phosphatase in verifying prostatic carcinoma involvement in seminal vesicles: a study of 57 cases of radical prostatectomy specimens of pathologic stage pT3b., PMID:20586625

Protein complexes/aggregates as potential cancer biomarkers revealed by a nanoparticle aggregation immunoassay., PMID:20392611

Prostatic acid phosphatase is expressed in peptidergic and nonpeptidergic nociceptive neurons of mice and rats., PMID:20084276

[New drugs in metastatic castration-resistant prostate cancer]., PMID:20022854

Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer., PMID:19636017

Datasheet

Document Download

Anti-ACP3 Antibody (R1P65).pdf

 

$ 290
Product specifications
50 μg 290 100 μg 484

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-ACP3 Antibody (R1P65) [RHD10102]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only